As per Global Insight services’ assessment, about 10+ prominent pharma and biotech giants are working on 10+ drugs in the Male Hypogonadism – pipeline landscape globally. Male Hypogonadism Pipeline Insight, 2023” report by Global Insight Services provides a comprehensive analysis of the ongoing clinical development activities and growth prospect.
Download PDF Sample Pages to Get an in-depth Assessment of the Emerging Therapies and Key Companies: https://www.globalinsightservices.com/request-sample/GIS31269
Male Hypogonadism is characterized by a decrease in testosterone level or lack of spermatozoa production or both. When a disorder related to the testes it is called primary hypogonadism or if it related to the hypothalamic-pituitary axis it is called secondary hypogonadism.
Causes of hypogonadism include HIV or AIDS, Klinefelter syndrome, Kallmann syndrome, injury to testicles, and untreated sleep apnea.
Symptoms of hypogonadism include fatigue, hot flashes, infertility, decrease in muscle mass, and loss of bone mass
Report Highlights
Global Insight Service’s, Male Hypogonadism – Drug Pipeline Landscape, 2023 report provides an overview of the Male Hypogonadism pipeline drugs. This report covers detailed insights on Male Hypogonadism drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Male Hypogonadism pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.
Key Players
- Chong Kun Dang Pharmaceutical
- Clarus Therapeutics Inc
- Diurnal Limited
- EndoCeutics Inc
- Function Promoting Therapies LLC
- Hypospraypharma
- IASO BioMed Inc
- Lennham Pharmaceuticals Inc
- Lipocine Inc
Purchase your copy now: https://www.globalinsightservices.com/checkout/single_user/GIS31269
Report Covers the Emerging Pipeline Products Under Different Phases of Clinical Development Like –
– Late-stage products (Phase III)
– Mid-stage products (Phase II)
– Early-stage product (Phase I)
– Pre-clinical and Discovery stage candidates
– Discontinued & Inactive candidates
About Global Insight Services:
Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.
Contact Us:
Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: [email protected]
Phone: +1-833-761-1700